Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. develops and manages licensed healthcare assets while advancing a pipeline of novel, multifunctional biotherapeutics for oncology. Company news centers on Ziihera (zanidatamab-hrii) and zanidatamab-related regulatory and clinical updates, including HER2-targeted development, as well as ZW191, a folate receptor alpha-targeting antibody-drug conjugate with Fast Track designation for advanced or metastatic platinum-resistant ovarian cancer.
Recurring updates also cover antibody-drug conjugate platform work, including RAS inhibitor ADC programs and targets such as CLDN18.2, Ly6E and PTK7, along with financial results, cash resources, share repurchase activity, investor conference participation and executive leadership appointments.
Zymeworks (Nasdaq: ZYME) will report first quarter 2026 financial results after market close on May 7, 2026. Management will host a conference call and live webcast the same day at 4:30 PM ET to discuss results and provide a corporate update. Webcast replay and dial-in details will be available on the company website.
Zymeworks (Nasdaq: ZYME) announced full-time appointments of Dr. Adam Schayowitz as Executive VP & Head of R&D and Scott Platshon as Executive VP & Chief Business Officer, effective April 9, 2026.
Both report to CEO Kenneth Galbraith and will advance clinical programs, asset aggregation, and management of licensed assets including Ziihera and pasritamig. The company cited Phase 1 initiation for ZW251 and positive Phase 3 HERIZON-GEA-01 data for zanidatamab as momentum supporting its integrated R&D and partnership strategy.
Zymeworks (Nasdaq: ZYME) appointed Kristin Stafford as Chief Financial Officer, effective April 1, 2026. Ms. Stafford joins from Royalty Pharma with experience in strategic planning, capital markets, acquisitions and SEC reporting. She is a CPA, holds a B.Sc. in business administration and serves on the Novocure board.
This leadership hire aims to support disciplined capital allocation and execution of Zymeworks' strategic priorities.
Zymeworks (Nasdaq: ZYME) announced the U.S. FDA granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for advanced or metastatic platinum‑resistant ovarian cancer (PROC) on March 30, 2026.
ZW191 is in an ongoing Phase 1 study (NCT06555744) evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity; FRα is reported in ~75% of high‑grade serous ovarian carcinomas, >50% of endometrial cancers, and ~70% of lung adenocarcinomas.
Zymeworks (Nasdaq: ZYME) announced management will participate in two investor conferences in April 2026: Needham 25th Annual Virtual Healthcare Conference and Bloom Burton & Co. Healthcare Investor Conference.
Presentations: April 15, 2026 at 10:15 AM ET (virtual) and April 21, 2026 in Toronto, ON. According to the company, management will hold one-on-one meetings and investor presentations at both events.
Zymeworks (Nasdaq: ZYME) announced four presentations at the AACR Annual Meeting (April 17-22, 2026) featuring data on Ziihera (zanidatamab-hrii), presented by partner Jazz Pharmaceuticals. Highlights include NeoZanHER Phase 2 neoadjuvant results with a statistically significant tumor-size reduction at six weeks and 30% pCR (n=6).
Additional abstracts cover mechanistic multi-omics of differentiated HER2 biology, activity after T-DXd, tumor-agnostic Phase 2 data, and adaptive biomarker-driven organ-preservation strategies in gastroesophageal adenocarcinoma.
Zymeworks (Nasdaq: ZYME) will present clinical and preclinical data at the AACR Annual Meeting April 17–22, 2026, including an oral presentation on April 21 reporting Part 1 results from the Phase 1 ZW191 dose‑escalation study.
Multiple posters (April 20–21) describe a novel pan‑RAS inhibitor ADC platform and preclinical candidates (ZW418, ZW427, ZW439, ZW437) showing potent activity and encouraging tolerability in RAS‑mutant cancer models.
Zymeworks (NASDAQ: ZYME) entered a $250 million non-recourse, royalty-backed note financing with Royalty Pharma on March 2, 2026. Repayments come from 30% of worldwide tiered royalties on Ziihera until repaid; Zymeworks retains 70% of royalties during repayment.
Royalty Pharma stops receiving payments after cumulative receipts of 1.65x the note by December 31, 2033 or 1.925x thereafter. Proceeds are non-dilutive, support share repurchases, potential strategic acquisitions, and extend cash runway beyond 2028. Zymeworks keeps up to $1.5 billion in remaining milestone payments tied to Ziihera.
Zymeworks (Nasdaq: ZYME) reported 2025 revenue of $106.0M (up 39% YoY) and a reduced net loss of $81.1M (down 34% YoY). Cash and marketable securities were $270.6M at year-end. The company closed a $250M non‑recourse royalty‑backed note and used $62.5M for share repurchases to March 2, 2026. Ziihera received approvals in Canada and the UK for biliary tract cancer, Jazz plans a potential U.S. GEA launch in 2H 2026, and up to $440M in GEA milestones are eligible.
Zymeworks (Nasdaq: ZYME) will report fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Management will host a conference call and webcast the same day at 8:30 am Eastern Time to discuss results and provide a corporate update.